

# Index

---

## A

- Abrams-Griffith number, 180
- Abscess
  - pelvic, 88
  - perinephric, 84
  - peri-urethral, 123
  - prostatic, 123
  - scrotal, 224
- Acetoacetic acid, 11–12
- Acetone, 11–12
- Acidosis, renal tubular, 9, 38–40
- Adenocarcinoma, prostatic, 105
- Adenoma, adrenal, imaging
  - of, 98, 101, 105
- Adrenal disease, 66
- Adrenal function
  - serum markers of, 64, 66–68, 244
  - urinary markers of, 40–42, 244
- Adrenal glands
  - calcification of, 71
  - imaging of
    - with computed tomography, 89, 244
    - with magnetic resonance imaging, 101
    - with ultrasound, 85
- Adrenal hormone assays, 40–42, 64, 66–68, 244
- Adrenaline, 43, 68
- Adrenal-specific urinary tests, 40–42
- Adrenal tumor markers, 244
- Adrenal tumors, 244
  - imaging of
    - with computed tomography, 97–98, 244
    - with magnetic resonance imaging, 101, 105
    - with ultrasound, 80
- Adrenocorticotropic hormone (ACTH), 66, 67
- Alanine, 35
- Albumin, 10, 29
- Aldosterone, 40, 41, 64, 67
- Aldosterone-18-glucuronide, 41
- Alkaline phosphatase, as bone activity marker, 61, 62, 63
- Allergic reactions, to contrast media, 72, 114
- Alpha fetoprotein, 55, 58, 59, 60, 61
- 5-Alpha-reductase inhibitors, 50–51
- Ambulatory urodynamics, 189–192
- American Association for the Surgery of Trauma, 97

- Amino acids, 35  
Aminobutyric acid, 35  
Ammonium, 33  
Ammonium chloride loading test, 39–40  
Androgens, 40, 42, 64, 66  
Andrology, 258–266  
    erectile dysfunction, 63, 64, 85, 106, 118, 127–129, 258–260  
    male infertility, 63, 64, 195, 213–216, 260–266  
    Peyronie's disease, 86, 106, 127, 258, 260, 262  
Androstenedione, 40, 64  
Aneurysms, imaging of, 87  
Angiomyolipomas, 242  
    imaging of, 95  
Angiotensin II, 143–144  
Anti-epileptic medication, 42  
Antipsychotic medication, 42  
Anti-sperm antibodies, 216, 264  
Anxious bladder syndrome, 232  
Aortic calcification, imaging of, 71  
Arginine, 35  
Arteriography, penile, 261  
Arteriovenous fistulae, imaging of, 84  
Arteriovenous malformations, imaging of, 87  
Asparagine, 35  
Aspartic acid, 35  
Aspiration, of renal cysts, 207–208  
Asthenospermia, 216  
Azoospermia, 215, 265
- B**  
Bacterial count, in urine, 16, 17, 18, 19. *See also* Bacteriuria  
Bacteriuria  
    asymptomatic, 253  
    in children, 253  
    significant, 17, 18, 253  
    urine dipstick detection of, 11  
Balanitis xerotica obliterans, 247  
Becquerels (Bq), 132  
Bed wetting. *See* Enuresis, nocturnal  
Bence-Jones protein, 28  
Benign prostatic hypertrophy (BPH), 47, 49, 50–51, 227  
    calcification associated with, 198  
    as hematuria cause, 241  
Bilirubin, 12  
Biofeedback, during pelvic floor relaxation training, 192  
Biopsy  
    penile, 247  
    prostate, 195, 246  
    transrectal ultrasound-assisted, 198–200  
    testicular, 265  
Bladder  
    hypotonic, videourodynamic evaluation of, 188  
    imaging of  
        with computed tomography, 87, 89  
        with cystography, 118–122  
        with cystoscopy, 216–217  
        with Doppler studies, 118  
        with magnetic resonance imaging, 105  
        with ultrasound, 81, 85  
    incomplete emptying of, 232

- "lazy," 257  
 neurogenic  
   ambulatory urodynamic  
     evaluation of, 189  
   in children, 257  
   cystometry of, 174  
   as vesicoureteral reflux  
     cause, 251  
   videourodynamic  
     assessment of, 186  
   rupture of, imaging of, 120,  
     121-122  
   "teardrop," 121  
 Bladder cancer/tumors  
   imaging of  
     with computed  
       tomography, 98  
     with cystoscopy, 217  
     with magnetic resonance  
       angiography, 102  
     with magnetic resonance  
       imaging, 101, 105  
     with positron emission  
       tomography, 159,  
       161  
   TNM classification of,  
     244-245  
 Bladder catheterization,  
   210-213  
 Bladder compliance,  
   ambulatory  
   urodynamic  
   evaluation of, 191  
 Bladder neck  
   dyssynergia of, 232  
   obstruction of, 226  
   videourodynamic evaluation  
   of, 187-188  
 Bladder outlet obstruction  
   (BOO), 226-227  
   ambulatory urodynamic  
   evaluation of, 191  
   frequency volume chart  
   patterns in, 164-165  
   pressure-flow cystometry of,  
     174, 180  
   residual bladder urine  
     volume in, 173  
   symptoms of, 231, 232  
   urine flow rate studies of,  
     166, 169, 170-171  
   videourodynamic evaluation  
   of, 186  
 Bladder pain, chronic,  
   229-230  
 Bladder retraining, frequency  
   volume charts in,  
   165  
 Bladder surgery, cystography  
   following, 119, 120,  
   122  
 Bladder trauma, imaging of,  
   98-99, 119, 120,  
   121-122  
 Bladder tumor antigen, 44, 45  
 Blood, in urine, 7, 9  
 Blood flow  
   penile, 82, 85, 127-129  
   pudendal, 85  
   renal, 83, 84  
   scrotal, 85  
   testicular, 118  
 Blood sampling, for  
   glomerular filtration  
   rate estimation,  
   150-151  
 Blood tests, 47-68  
   for bone disease related to  
   urology, 61-63  
   for electrolyte disturbances  
   detection, 54-55,  
   56-57  
   male sex hormone profile,  
   63-64, 66  
   prostate-specific antigen  
   (PSA) assay, 46,  
   47-54, 109, 155, 156,  
   195, 245, 246

- Blood tests (*cont.*)  
  serum markers of adrenal function, 64, 66–68, 244  
  testicular tumor markers, 55, 58–61
- Bone disease, related to urology, 61–63
- Bone scans, 152–157  
  advantages and disadvantages of, 157  
  comparison with positron emission tomography, 162  
  indications for, 152, 246, 247, 249  
  interpretation of, 153–157  
  metastatic hot spots on, 154, 155  
  normal, 154  
  radiation dose in, 153  
  technique, 152–153
- Bone tumor treatment, bone scans following, 156–157
- Bony abnormalities, imaging of, 71
- Bowenoid papulosis, 247
- Bowen's disease, 247
- Breast cancer, skeletal metastatic, 154
- Breastfeeding, as  
  contraindication to positron emission tomography, 159  
  and radiopharmaceuticals, 136
- Brown-Wickham perfusion technique, 183
- C**
- Calcification, imaging of  
  prostatic, 198  
  renal, 70, 72, 198
- Calcitonin, 61
- Calcium. *See also*  
  Hypercalcemia;  
  Hypocalcemia  
  as bone activity marker, 62, 63  
  urine content of, 32, 35
- Calculi, renal  
  analysis of, 200–203  
  bone disease associated with, 61  
  calcium, 201, 203  
  cystine, 9, 34, 203  
  frequency of, 203  
  as hematuria cause, 241  
  imaging of  
    with computed tomography, 87, 89, 96  
    with intravenous urography, 72, 73  
    with nephrostography, 111  
    with plain abdominal radiographs, 69, 70, 71  
    with ultrasound, 80, 85  
  continent pouch, 237  
  as loin pain cause, 234–237  
  oxalate, 203  
  phosphate, 203  
  recurrent, 200  
    urinalysis of, 30–34  
  with renal tubular acidosis, 39  
  struvite, 203  
  ureteral  
    as hematuria cause, 241  
    imaging of, 102  
    as loin pain cause, 234  
  uric acid, 9  
  urine pH and, 9

- Candida albicans*, 16
- Captopril-enhanced MAG3 renography, 143–144
- Carbamazepine, 42
- Carcinoma *in situ* (CIS), urine cytological analysis of, 22
- Casts, urinary, 15
- Catecholamine metabolites assessment, 68
- Catecholamines, 42, 43, 66
- Catheterization, of the bladder, 210–213  
indwelling, for urine collection, 4–5, 22  
intermittent, for urine collection, 4
- Cavernosography, 127–129, 261
- Cavernosometry, 127, 128–129  
dynamic infusion, 261
- Chemotherapy, bone scans following, 156–157
- Children. *See* Pediatric patients
- Chlamydia trachomatis*, 209, 210
- Chloride, urine content of, 38
- Choriocarcinoma, 59, 248
- Chromium, as radionuclide, 133, 135
- Citrate, 33
- Citrulline, 35
- Cockcroft and Gault equation, for glomerular filtration rate estimation, 26
- Colic  
renal, 234  
ureteric, 234, 235–236
- Computed tomography (CT), 87–99  
advantages and disadvantages of, 99  
in combination with fistulography, 131  
comparison with magnetic resonance imaging, 104  
positron emission tomography, 160, 161  
contrast media use in, 89–91  
enhancement (Hounsfield units) in, 91  
indications for, 87–89  
male infertility, 265  
renal calculi, 235  
testicular tumors, 160, 161, 249  
interpretation of, 93–99  
radiation dose in, 93  
as replacement for intravenous urography, 72  
technique, 89–92  
as virtual endoscopy, 92
- Condyloma acuminatum, 247
- Congenital disorders, 123, 125, 250–257. *See also* Pediatric patients
- Conn's syndrome, 66
- Contrast media  
adverse reactions to, 72, 76–79, 114, 122  
in cavernosography, 128  
in computed tomography, 89–91  
in cystography, 118–119, 120, 121, 122  
in Doppler studies, 118  
in intravenous urography, 72, 76–79

- Contrast media (*cont.*)  
  iodine-containing, 72  
  in magnetic resonance imaging, 103, 104  
  in nephrostography, 112, 113, 114  
  in retrograde ureteropyelography, 116  
  in ultrasound scanning, 82–83  
  in urethrography, 124
- Cortisol, 40, 41, 64, 66, 67
- Creatinine  
  abnormal levels of, 56–57  
  serum content of, 26–27  
    in bladder outlet obstruction, 226  
    in pediatric hydronephrosis, 252  
  urine content of, 33
- Creatinine clearance, 27–28
- Cryptorchidism, 215  
  laparoscopy for, 205–206, 256
- Crystals, urinary, 15–16
- Cushing's syndrome, 66
- Cutaneous horn, penile, 247
- Cystatin, 26
- Cystine, 34, 35
- Cystinuria, 31, 34
- Cystitis  
  acute, 18  
  bacterial, 241  
  in children, 253  
  as hematuria cause, 241  
  interstitial, 229–230, 232, 241  
  radiation, 241
- Cystography, 118–122  
  advantages and disadvantages of, 122  
  indications for, 119  
  interpretation of, 121–122  
  technique, 119–121  
    indirect micturating, 145  
    micturating cystourethrography (MCUG), 120–121, 122–127
- Cystometry  
  pressure-flow, 173–181  
    indications for, 174  
    interpretation of, 176–181  
    limitations to, 181  
    technique, 175–176  
  with sphincter electromyography, 193–194  
  with videourodynamics (VUDS), 186
- Cystoscopes, rigid or flexible, 218, 219
- Cystoscopy, 216–219  
  for bladder outlet obstruction evaluation, 227  
  for chronic pelvic pain/interstitial cystitis evaluation, 230  
  in combination with retrograde ureteropyelography, 114–115  
  for pediatric hydronephrosis evaluation, 252
- Cystourethrography, micturating (MCUG), 120–121, 122–127  
  advantages and disadvantages of, 127  
  indications for, 123  
  interpretation of, 125–127  
  technique, 124
- Cysts  
  epidermal, 223  
  prostatic, 198

- renal, 243  
 aspiration of, 207–208  
 imaging of, 93–94  
 Cytology, 21–24
- D**
- DD3<sup>PCA3</sup> gene, 44, 46
- Dehydration  
 as contraindication to  
 diuretics, 139  
 effect on urine, 7, 9
- Dehydroepiandrosterone  
 (DHEA), 40, 42,  
 64
- Dehydroepiandrosterone  
 sulfate (DHEAS), 40,  
 42, 64
- Detrusor  
 hypotonic, 232  
 impaired contractility of  
 pressure-flow cystometry  
 of, 179–180  
 residual bladder urine  
 volume in, 173  
 overactive, 231  
 ambulatory urodynamic  
 evaluation of, 190,  
 191, 192  
 frequency volume chart  
 patterns in, 165  
 pressure-flow cystometry  
 of, 177–178  
 urethral pressure profile  
 in, 184–185  
 urine flow rate studies of,  
 170, 171  
 as urine leakage cause,  
 227  
 as vesicoureteral reflex  
 cause, 251  
 underactive, urine flow rate  
 studies in, 171
- Detrusor-sphincter  
 dyssynergia, 232
- pressure-flow cystometry of,  
 180–181  
 sphincter electromyography  
 of, 192, 194  
 urethral pressure profile in,  
 185  
 urine flow rate studies in,  
 168, 169
- Dexamethasone suppression  
 test, 67
- Diabetes mellitus, 10  
 as erectile dysfunction  
 cause, 258, 259  
 ketoacidosis of, 11
- Dimercaptosuccinic acid  
 (DMSA) renography,  
 133, 134, 146–148
- Diuretics, contraindication in  
 dehydrated patients,  
 139
- Diverticula  
 of the bladder, 232  
 imaging of, 119, 217  
 urethral, imaging of, 125
- DNA ploidy (flow cytometry),  
 19–21
- Doppler studies, 117–118  
 color, 81–82, 117  
 duplex, 117  
 penile, 127  
 for erectile dysfunction  
 evaluation, 85  
 of hydroceles, 225  
 power, 117  
 of testicular torsion, 225
- Drugs. *See also names of  
 specific drugs*  
 effect on adrenal cortical  
 hormone assays,  
 42
- Dutasteride, 50
- Dysuria  
 cystoscopy-related, 219  
 renal calculi-related, 236

- Dysuria (*cont.*)  
sexually transmitted  
infection-related, 209
- E**
- Electrolyte disturbances,  
54–55, 56–57  
hypoadrenalism-related, 67
- Electrolytes, urinary, 34–38
- Electromyography (EMG),  
sphincter, 192–194
- Embryonal carcinoma, 59,  
248
- Endoscopy, virtual, 92–93
- Enuresis  
diurnal, 257  
nocturnal, 231, 256–257
- Epididymitis, 223–224
- Epithelial cells, urine content  
of, 15
- Erectile dysfunction (ED), 63,  
64, 258–260  
cavernosographic  
evaluation of,  
127–129  
Doppler studies of, 85  
magnetic resonance  
imaging evaluation  
of, 106  
penile vasculature imaging  
in, 85, 118  
ultrasound evaluation of,  
85
- Erythroplasia of Queyrat, 247
- Escherichia coli*, 18, 253
- Ethylenediamine tetraacetic  
acid (EDTA), 135,  
149, 150, 151
- F**
- $\alpha$ -Fetoprotein, 55, 58, 59
- Fibrinogen degradation  
products (Accu-Dx),  
44, 45
- Fibroids, uterine, calcified, 71
- Fibrosis, retroperitoneal,  
imaging of, 101
- Filling defects, imaging of  
with computed tomography,  
87  
with intravenous urography,  
75  
with retrograde  
ureteropyelography,  
114, 115  
with urethrography, 125
- Finasteride, 50
- Fistulae  
colo-vesical, 228  
imaging of, 119, 120, 122  
with fistulography,  
130–131  
with urethrography, 123  
of lower urinary tract,  
228  
renocutaneous, 131  
uretero-vaginal, 228  
urethro-rectal, 228  
urethro-vaginal, 228  
vesical, 119, 120, 122  
vesico-vaginal, 228, 231
- Fistulography, 130–131
- Flow cytometry (DNA ploidy),  
19–21
- Flow rate studies, 166–171
- <sup>18</sup>Fluorine-2-D-deoxyglucose  
(FDG), 158,  
160–162
- Follicle-stimulating hormone  
(FSH), 63, 65, 66,  
256, 261, 263
- Foreign bodies  
in the bladder, 231  
in the urinary tract,  
imaging of, 69
- Fowler's syndrome, 192, 194
- Frequency volume charts,  
163–165



- for bladder outlet obstruction
    - evaluation, 227
  - for pediatric urinary incontinence
    - evaluation, 257
  - prior to the pad test, 204
  - Fructose testing, seminal, 216
- G**
- Gas, intestinal, imaging of, 69, 70, 71, 72
  - Genetic testing, for male infertility evaluation, 265
  - Genitalia, external, imaging of, 106
  - Germ cell tumors, testicular, 55, 60–61, 248
  - Glomerular filtration rate (GFR), 25–27, 28
    - estimation of, 26–27, 148–151
    - urine flow rate in, 139
  - Glomerulonephritis, as
    - hematuria cause, 241
  - Glucocorticoid excess, 66, 67
  - Glucosuria, 10, 11
  - Glutamic acid, 35
  - Glycine, 35
  - Glycosuria. *See* Glucosuria
  - Granulosa cell tumors, 248
- H**
- Hematoma, 84
    - pelvic, 121
    - renal, 207
  - Hematuria, 240–241
    - causes of, 241
      - cystoscopy, 219
      - glomerular, 13, 14
      - non-glomerular, 13, 14
      - renal blunt trauma, 96
      - renal calculi, 234, 236, 237
      - upper urinary tract infections, 238
    - cystoscopic analysis of, 217
    - dipstick detection of, 9
    - renal calculi-related, 234, 236, 237
    - ultrasound evaluation of, 80
    - urine color in, 7
    - urine microscopic
      - evaluation of, 12, 13, 14
  - Hemoglobin, peroxidase-like activity of, 9
  - Hemoglobinuria, 7, 9, 13
  - Hinman's syndrome, 257
  - Histidine, 35
  - Homocystine, 35
  - Homsy's sign, 143
  - Hounsfield units (HU), 91
  - $\beta$ -Human chorionic gonadotropin ( $\beta$ hCG), 55, 58, 59, 60, 61, 256
  - Hyaluronic acid/hyaluronidase (HA-HAase test), 44, 45
  - Hydration, effect on urine, 8
  - Hydroceles, 225
  - Hydronephrosis, 235
    - in children, 250–252
    - imaging of
      - with computed tomography, 87, 95
      - with ultrasound, 80, 84
  - Hydroureteronephrosis, in children, 250
  - Hyperaldosteronism, 66, 67
  - Hypercalcemia, 57
    - bone disease-related, 61, 62
    - malignancy-related, 63
    - renal effects of, 61–62
  - Hypercalciuria, 34, 39, 61
  - Hyperglycemia, 10

- Hyperkalemia, 37, 38, 56  
  hypoadrenalism-related, 67  
Hyponatremia, 56  
Hyperparathyroidism, 61, 63  
Hyperphosphaturia, renal  
  tubular acidosis-  
  related, 39  
Hypertension  
  renovascular, 144  
  vesicoureteral reflux-related,  
  251  
Hypoadrenalism, 66, 67  
Hypoaldosteronism, 66, 67  
Hypocalcemia, 57  
Hypokalemia, 37–38, 56  
Hyponatremia, 36, 56  
  hypoadrenalism-related, 67  
Hypo-osmotic swelling test,  
  216  
Hypothalamic-pituitary-  
  gonadal axis, 63
- I**  
Ileal conduits, urine collection  
  from, 5  
Immocyst, 44, 45  
Impotence. *See* Erectile  
  dysfunction  
Infants. *See* Pediatric patients  
Infertility, in males, 63, 64  
  definition of, 213  
  etiology of, 262  
  evaluation of, 63, 195,  
  213–216, 260–263  
Inflammation  
  pelvic inflammatory disease,  
  209  
  prostatic, 49–50  
  renal, imaging of, 96  
Infrared spectroscopy, of  
  renal calculi, 201,  
  202  
International Continence  
  Society, 180, 193  
International Prostate  
  Symptoms Score  
  (IPSS), 233  
International Reflux Study  
  Committee, 251  
Intracavernous injections, for  
  erectile dysfunction  
  evaluation, 261  
Intratubular germ cell  
  neoplasia, 248  
Intravenous pyelography. *See*  
  Intravenous  
  urography (IVU)  
Intravenous urography (IVU),  
  72–79  
  advantages of, 75–76  
  in children, 75, 252  
  contrast media in, 72  
  toxicity of, 76–79  
  drawbacks to, 76  
  indications for, 72, 235  
  interpretation of, 74–75  
  radiation dose in, 74  
  technique, 72–74  
Intrinsic sphincter deficiency,  
  179  
Iodine, as radionuclide, 133,  
  135  
Isoleucine, 35  
Isotopes, 132
- K**  
Ketoacidosis, diabetic, 11  
Ketones, 11–12  
17-Ketosteroids, 41, 42  
Kidneys, imaging of  
  with computed tomography,  
  87–88, 93–98  
  with Doppler studies, 118  
  with magnetic resonance  
  imaging, 100–101,  
  104–105  
  with plain abdominal  
  radiographs, 70

- with  $^{99m}\text{Tc}$ -DMSA  
renography, 146–148  
with ultrasound, 81, 83–85
- L**
- Lactate dehydrogenase (LDH),  
55, 58, 59, 60  
LD1 isoenzyme of, 60–61  
*Lactobacilli*, 16  
Laparoscopy, for  
undescended testis  
(cryptorchidism)  
evaluation, 205–206,  
256  
Leak point pressure (LPP),  
179  
Leucine, 35  
Leukocyte esterase test, 11  
Leukoplakia, 247  
Leydig cell tumors, 248  
Linear passive urethral  
resistance relation  
(LinPURR), 180  
Loin pain, 234–239, 242  
Lower urinary tract symptoms  
(LUTS), 226–233  
ambulatory urodynamics of,  
189  
bladder outlet obstruction-  
related, 226–227  
cystometry of, 174  
frequency volume charts of,  
163–165  
irritative, 234  
posterior urethral  
valve-related, 254  
renal calculi-related, 234,  
236  
urinary incontinence-  
related, 227–228  
stress, 227–228  
urge, 228  
urine low rate studies of,  
171  
videourodynamic evaluation  
of, 186  
Lung cancer, with skeletal  
metastases, 154  
Luteinizing hormone (LH),  
63, 64, 65, 66, 256,  
261, 263  
Luteinizing hormone-  
releasing factor  
(LHRH), 63, 64, 65  
Lymph nodes, calcified,  
imaging of, 71  
Lymphoma  
renal, imaging of, 94, 100  
testicular, 248  
Lysine, 35
- M**
- Magnesium, 33  
Magnetic resonance  
angiography, 101,  
104  
Magnetic resonance imaging  
(MRI), 99–106  
advantages and  
disadvantages of,  
106  
in combination with  
fistulography, 131  
magnetic resonance  
spectroscopy, 107,  
108  
comparison with  
computed tomography,  
104  
magnetic resonance  
spectroscopy, 109  
contraindications to,  
101–102  
contrast media in, 103, 104  
indications for, 100–101,  
103, 247, 265  
interpretation of, 104–107  
penile, 247, 262

- Magnetic resonance imaging (MRI) (*cont.*)  
during pregnancy, 101–102, 104  
technique, 101–104
- Magnetic resonance spectroscopy  
advantages and disadvantages of, 109–110  
in combination magnetic resonance imaging, 107, 108  
comparison with magnetic resonance imaging, 109  
indications for, 107  
interpretation of, 108–109  
technique, 108
- Magnetic resonance urography, 101, 104–105  
during pregnancy, 102
- Medronate (<sup>99m</sup>technetium-methylenediphosphate), 152–153
- Metanephrine, 42, 43
- Metastases  
adrenal, 98  
imaging of, 71  
skeletal, bones scan of, 154, 156–157
- Metformin, contrast-related nephrotoxicity and, 76, 79
- Methionine, 35
- Microscopy  
polarizing, of renal calculi, 202  
scanning electron, of renal calculi, 202  
of urine, 3, 12–17  
of bacteria, 16  
of casts, 15  
of crystals, 15–16  
of epithelial cells, 15  
of parasites, 16  
of red blood cells, 13  
technique, 12  
of white blood cells, 13  
of yeast, 16
- Milk-alkali syndrome, 62
- Modification of Diet in Renal Disease (MDRD) equation, for glomerular filtration rate estimation, 26, 28
- Multiple myeloma, 28
- Mycobacterium tuberculosis*, 230
- Myoglobinuria, 7, 9  
urine microscopy of, 13
- N**
- Necrosis, papillary, as hematuria cause, 241
- Neisseria gonorrhoea*, 209, 210
- Nephrocalcinosis. *See also* Calculi, renal imaging of, 71
- Nephrolithiasis. *See* Calculi, renal
- Nephropathy, as hematuria cause, 241
- Nephrostography, 110–114  
advantages and disadvantages of, 113–114  
contraindications to, 111  
contrast media use in, 112, 113, 114  
indications for, 110  
interpretation of, 113  
radiation dose in, 113  
renal puncture in, 110, 112, 114

- technique, 111–112  
Whitaker's test with, 110, 113
- Nitrites, 11
- Nocturia, 231
- Nocturnal penile tumescence and rigidity test, 261
- Noradrenaline, 43, 68
- Nuclear matrix protein (NMP22), 44, 45
- Nuclear medicine, 132–162  
bone scans, 152–157  
glomerular filtration rate (GFR) estimation, 148–151  
Gates technique, 150  
positron emission tomography (PET) scans, 157–162  
renography  
MAG3, 133, 135, 136–145  
<sup>99m</sup>technetium-DMSA, 133, 134, 146–148
- O**
- Oligospermia, 215, 265
- Oncocytoma, 242  
imaging of, 95
- Ornithine, 35
- Osteomalacia, 63
- Osteoporosis, 62–63
- Oxalate, 33
- P**
- Pad test, for urinary incontinence, 203–205
- Pain  
chronic pelvic/bladder, 229–230  
scrotal, non-tumor-related, 223–225  
suprapubic, 232  
urethral, 209  
urethral pain syndrome, 229
- Painful bladder syndrome, 229
- Parasites, urine content of, 16
- Parathyroid hormone, as bone activity marker, 61, 62, 63
- Parathyroid hormone-related peptide, 62
- Parenchymal disease, as hematuria cause, 241
- Parenchymal perfusion, imaging of, 83
- Pediatric patients, 250–257  
cystography in, 119, 120, 121, 122  
indirect micturating cystography in, 145  
MAG3 renography in, 138–139, 145  
proteinuria in, 29  
sphincter electromyography in, 192  
undescended testis (cryptorchidism) in, 205–206, 255–256  
urine collection in, 5, 6  
urine flow rate studies in, 167  
videourodynamics in, 186
- Pelvic/alyceal system, imaging of  
with nephrostography, 110, 112  
with retrograde ureteropyelography, 114
- Pelvic floor relaxation training, biofeedback during, 192
- Pelvic inflammatory disease, 209

- Pelvic pain, chronic, 229–230
- Pelvis
- fractures of, 121
  - imaging of
    - with computed tomography, 98–99
    - with magnetic resonance imaging, 105–106
- Penile carcinoma in situ, 247
- Penile tumors/cancer, 247
- imaging of, 101
- Penis, imaging of
- with Doppler studies, 118
  - with magnetic resonance imaging, 101, 106, 227
  - with ultrasound, 81–82, 85–86
- Peyronie's disease, 86, 106, 127, 258, 260, 262
- Phenylalanine, 35
- Pheochromocytoma, 66, 68
- adrenal hormone secretion in, 42
  - imaging of, 101, 105
- Phleboliths, imaging of, 71
- Phosphate
- as bone activity marker, 62, 63
  - inorganic, urine content of, 33
  - urine content of, 33, 35
- Placental alkaline phosphatase (PALP), 55, 58
- Polarizing microscopy, of renal calculi, 202
- Polyuria, 164
- nocturnal, 231
- Positron emission tomography (PET), 133, 157–162
- indications for, 159
  - radiation dose in, 160
  - technique, 159–160
- Post-coital test, for erectile dysfunction evaluation, 263
- Post-voiding residual (PVR) urine, estimation of, 172–173
- Potassium. *See also* Hyperkalemia; Hypokalemia
- urine content of, 35, 37–38
- Pregnancy
- as contraindication to intravenous urography, 72
  - magnetic resonance imaging, 101–102
  - positron emission tomography (PET), 159
  - retrograde ureteropyelography, 115
  - ketone production during, 11
- Pressure-flow cystometry studies, 173–181
- Priapism
- cavernosographic evaluation of, 127
  - cavernosography-related, 129
  - high- *versus* low-flow, 118
  - ultrasound evaluation of, 86
- Prolactin, 64, 65, 66, 259
- Prostate cancer, 245–247
- imaging of
    - with computed tomography, 98
    - with magnetic resonance imaging, 101, 105–106, 246
    - with magnetic resonance spectroscopy, 108–109

- with positron emission tomography, 161–162
- with transrectal ultrasound (TRUS), 195, 197, 246
- metastatic, 161–162
  - bone scans of, 154–156, 246
- prostate-specific antigen (PSA) assay for, 46, 47–54
- prostatic biochemical changes in, 108, 109
- staging of
  - with bone scans, 156
  - with prostate-specific antigen (PSA), 53–54
  - with transrectal ultrasound, 195
- TNM classification of, 246
- urinary markers for, 44, 46
  - prostate-specific antigen (PSA), 44, 46, 47–54, 109, 155, 156, 195, 245, 246
- Prostate capsule, transrectal ultrasound evaluation of, 198
- Prostatectomy, stress incontinence following, 186
- Prostate gland
  - imaging of
    - with computed tomography, 89
    - with magnetic resonance imaging, 105–106
    - with transrectal ultrasound (TRUS), 195–200
    - with ultrasound, 81
    - zonal anatomy of, 197
- Prostate pain syndrome, 229, 230
- Prostate-specific antigen (PSA), 44, 46, 47–54, 109, 245, 246
  - for cancer staging, 53–54
  - clinical implications of, 48–54
  - correlation with skeletal metastases, 155, 156
  - indications for, 47–48
  - modifications of, 51–53
  - normal values in, 48
  - as prostatic transrectal ultrasound indication, 195
  - technique, 48
- Prostate surgery, cystography following, 119, 120, 122
- Prostatic intraepithelial neoplasia (PIN), 195
- Prostatitis, 230
  - chronic, 195
  - prostate-specific antigen levels in, 49–50
  - prostatic calcification associated with, 71
- Protein
  - urinary excretion of, estimation of, 28–30
  - urine content of, 9–10
- Proteinuria, 9–10
  - hematuria-associated, 14
  - protein excretion test for detection of, 28
  - types of, 29–30
- Proteus*, 9, 18
- Psychiatric assessment, of erectile dysfunction patients, 261
- Pyelography, intravenous. *See* Intravenous urography (IVU)
- Pyelonephritis
  - in children, 253
  - as hematuria cause, 241

Pyridium, 204

Pyuria, 11, 13

## R

Radiation therapy, bone scans following, 156–157

Radiographs, plain abdominal (KUB), 69–72

advantages and disadvantages of, 71–72

in combination with intravenous urography, 72

indications for, 69, 234–235, 262

interpretation of, 69–71

radiation dose in, 69

technique, 69

comparison with bone scans, 157

Radiology, 69–131

cavernosography, 127–129

computed tomography, 87–99

cystography, 118–122

Doppler studies, 85, 117–118, 127

fistulography, 130–131

intravenous urography, 72–79

magnetic resonance imaging, 99–106

magnetic resonance spectroscopy, 107–110

nephrostography, 110–114

plain abdominal radiographs, 69–72

retrograde ureteropyelography, 114–116

ultrasound scanning, 80–87

urethrography, 122–127

Radionuclide imaging. *See also* Nuclear medicine

of testicular torsion, 225

Radiopharmaceuticals, 132–139

Rectal examination, digital, 50

for bladder outlet obstruction diagnosis, 226

for prostate cancer diagnosis, 246

transrectal ultrasound evaluation of, 195, 197

Red blood cells, urine content of, 13

5- $\alpha$ -Reductase inhibitors, 50–51

Renal anomalies, imaging of, 147–148

Renal artery stenosis, imaging of

with computed tomography, 87, 97

with contrast-enhanced ultrasound, 82, 84

with intravenous urography, 75

with magnetic resonance imaging, 104

with MAG3 renography, 144

Renal cell carcinoma, 242

as hematuria cause, 241

imaging of, 88

with computed tomography, 94

with magnetic resonance imaging, 100

with positron emission tomography, 159

metastatic, bone scans of, 156



- TNM classification of, 242–243
- Renal cystic disease, ultrasound-based evaluation of, 80, 84
- Renal cyst puncture (RCP), 207–208
- Renal failure  
 posterior urethral valves-related, 255  
 vesicoureteral reflux-related, 251
- Renal masses and tumors, 242–243. *See also* Renal cell carcinoma  
 as hematuria cause, 241  
 imaging of  
 with computed tomography, 87, 90–91  
 with magnetic resonance imaging, 100–101, 104  
 with <sup>99m</sup>Tc-DMSA renography, 1471–48  
 with ultrasound, 80
- Renal puncture  
 in nephrostography, 110, 112, 114  
 of renal cysts, 207–208
- Renal transplants, imaging of  
 with computed tomography, 87  
 with magnetic resonance angiography, 101  
 with magnetic resonance imaging, 104  
 with MAG3 renography, 144–145
- Renal trauma  
 imaging of, 87, 96–98  
 severity assessment of, 97
- Renal vein thrombosis, imaging of  
 with contrast-enhanced ultrasound, 83, 84  
 with intravenous urography, 75
- Renography  
 diuresis, 138–139  
 equivocal results in, 113  
<sup>99m</sup>Tc-DMSA, 133, 134, 146–148  
<sup>99m</sup>Tc-MAG3, 133, 135, 136–145  
 advantages and disadvantages of, 145  
 captopril-enhanced, 143–144  
 in children, 252  
 deconvolution analysis of, 143  
 interpretation of, 140–141  
 modifications of, 143–144  
 of parenchymal scarring, 141–142  
 for renal transplant evaluation, 144–145  
 renogram curve patterns in, 140–141, 142–143  
 split renal function in, 141
- Residual bladder urine  
 volume estimation, 172–173  
 bladder catheterization for, 210
- Resistive index (RI), in obstructive uropathy, 118
- Retrograde ureteropyelography (RPG), 114–116
- Retroperitoneum, imaging of  
 with computed tomography, 88  
 with ultrasound, 81, 85  
 “Rim sign,” 97

- S**
- Saline suppression test, 67
- Scanning electron  
microscopy, of renal  
calculi, 202
- Scarring, renal  
imaging of  
with cystoscopy, 217  
with MAG3 renography,  
141–142  
with <sup>99m</sup>Tc-DMSA  
renography, 147, 148  
pediatric urinary tract  
infections-related,  
253  
vesicoureteral reflux-related,  
251
- Schaefer nomogram, of  
bladder outlet  
obstruction, 180
- Schistosomiasis, 16
- Schistosomiasis, as hematuria  
cause, 241
- Scintigraphy. *See also* Bone  
scans  
penile, 262
- Scrotal masses, painless, 248
- Scrotal pain and swelling,  
non-tumor-related,  
223–225
- Scrotum, imaging of, 81–82,  
85
- Semen analysis, 264  
computer-assisted, 263  
standard, 213–216
- Semen leukocyte analysis,  
216, 263
- Seminal fructose testing, 216
- Seminal vesicles, imaging of  
with computed tomography,  
89  
with transrectal ultrasound,  
198  
with ultrasound, 81
- Seminomas, 59, 161, 248
- Serine, 35
- Sertoli cell tumors, 248
- Sex cord stromal tumors,  
248
- Sex hormone profile, in  
males, 63–64, 66
- Sexually transmitted  
infections, urethral  
swab diagnosis of,  
208–210
- Single photon emission  
computed  
tomography (SPECT),  
147
- Sodium. *See also*  
Hyponatremia;  
Hypernatremia  
fractional excretion of  
(FE<sub>NA</sub>), 36  
urine content of, 34, 35,  
36–37
- Soft-tissue abnormalities,  
imaging of, 69, 71
- Spectroscopy, infrared, of  
renal calculi, 201,  
202
- Sperm. *See* Semen analysis
- Sperm-cervical mucus  
interaction, 216
- Sperm penetration assay, 216,  
264
- Sperm viability test, 264
- Sphincter electromyography  
(EMG), 192–194
- Spirolactone, 42
- Squamous cell carcinoma  
of the bladder, 244  
penile, 247
- Staphylococcus*, 16  
*Staphylococcus saprophyticus*,  
18
- Stents, ureteric, imaging of,  
69, 111

- Streptococcus*, 16
- Sub-fertility, in males. *See*  
 Infertility, in males
- Suprapubic pain, 232
- Surgery, ultrasound scanning  
 during, 86
- Synacthen test, 67
- T**
- Tamm-Horsfall protein, 15
- Taurine, 35
- <sup>99m</sup>Tcnetium, 133, 134–135
- <sup>99m</sup>Tcnetium-diethylenetriaminepentaacetic acid (DTPA), 149, 150, 151
- <sup>99m</sup>Tcnetium-dimercaptosuccinic (DMSA) renography, 133, 134, 146–148
- <sup>99m</sup>Tcnetium-mercaptoacetyl triglycerine (MAG3) renography, 133, 135, 136–145
- <sup>99m</sup>Tcnetium-methylenediphosphate (medronate), 152–153
- Telomerase, 44, 45
- Teratocarcinoma, 59
- Teratoma, 59, 248
- Teratozoospermia, 216
- Testicular germ cell tumors, 55, 60–61, 248
- Testicular torsion, 224–225  
 imaging of, 85, 106
- Testicular tumor markers, 55, 58–61, 249
- Testicular tumors, 248–249  
 positron emission tomography of, 159, 160–161
- TNM classification of, 248–249
- Testis  
 imaging of  
 with computed tomography, 89  
 with Doppler studies, 118  
 with magnetic resonance imaging, 101, 106  
 undescended, 255–256  
 bilateral, 256  
 laparoscopy for, 205–206, 256  
 unilateral, 256
- Testosterone, 63, 64, 65, 66, 261
- Thermogravimetry, of renal calculi, 202
- Threonine, 35
- Tranquilizers, effect on  
 adrenal cortical hormone assays, 42
- Transitional cell carcinoma, 244  
 flow cytometric analysis of, 19–21  
 as hematuria cause, 241  
 imaging of  
 with computed tomography, 92, 94–95  
 with magnetic resonance angiography, 102  
 with retrograde ureteropyelography, 115  
 urinary markers for, 42, 44, 45  
 urine cytological analysis of, 22–24
- Transrectal ultrasound (TRUS), 195–200, 230, 265
- Trichomonas vaginalis*, 16, 209
- Tryptophan, 35

- Tuberculosis  
  as hematuria cause, 241  
  renal, imaging of, 71
- Tyrosine, 35
- U**
- Ultrasound scanning (USS),  
  80–87  
  advantages and  
    disadvantages of,  
    86–87  
  in children, 83  
  contrast-enhanced, 82–83  
  Doppler-assisted, 117–118  
    color, 81–82, 117  
    duplex, 117  
    duplex penile, 127  
  for erectile dysfunction  
    evaluation, 85  
  of hydroceles, 225  
  penile, 127, 261, 262  
  of testicular torsion, 225  
  indications for, 80–81  
    bladder outlet  
      obstruction, 227  
    epididymitis, 224  
    penile cancer, 247  
    renal calculi, 235  
    testicular tumors, 249  
  interpretation of, 83–86  
  intraoperative, 86  
  for residual bladder urine  
    volume estimation,  
    172  
  scrotal, 264  
  technique, 81–82  
  transrectal (TRUS),  
    195–200, 230, 265  
  with videourodynamics, 187
- uPM3 assay, for prostate  
  cancer detection, 44,  
  46
- Urate, abnormal levels of, 57
- Urea, abnormal levels of, 56
- Ureteropelvic junction  
  obstruction (UPJO),  
    237–238  
  in children, 253
- Ureteropyelography,  
  retrograde (RPG),  
    114–116
- Ureters  
  duplicated, as vesicoureteral  
    reflex cause, 251  
  imaging of  
    with computed  
      tomography, 89  
    with Doppler studies, 118  
    with magnetic resonance  
      angiography, 102  
    with nephrostogram, 110  
    with plain abdominal  
      radiographs, 70  
    with ultrasound, 87  
  obstruction of, 238  
    imaging of, 85, 118  
  strictures of, 238  
  tumors of, 238
- Urethra  
  cystoscopy-related trauma  
    to, 219  
  hypermobility of, 179  
  imaging of, 122–127,  
    216–217  
  incomplete emptying of,  
    232  
  obstruction/stenosis of  
    in children, 254  
    posterior urethral  
      valves-related, 254  
    urethral pressure profile  
      in, 185  
  strictures of, 232  
    as bladder outlet  
      obstruction cause,  
      226  
    cystoscopy-related, 219  
    as hematuria cause, 241

- imaging of, 86, 123, 125
  - with cystoscopy, 217
- urine flow rate studies in, 169, 171
- trauma to, imaging of, 123, 125, 126
- videourodynamic evaluation of, 187
- Urethral closure pressure
  - maximal, 182
  - in stress incontinence, 184
- Urethral pain syndrome, 229
- Urethral pressure profile (UPP), 181–186
  - interpretation of, 184–186
  - maximal, 182, 184–185
  - resting, 182
  - stress, 182, 183, 184
  - during voiding, 182
- Urethral swabs, 208–210
- Urethral tumors
  - as hematuria cause, 241
  - imaging of, 123, 127
- Urethral valves, posterior, 254–255
- Urethritis, 232
  - as hematuria cause, 241
- Urethrography, 122–127
  - antegrade. *See*
    - Cystourethrography,
    - micturating (MCUG)
  - indications for, 123
  - interpretation of, 125–127
  - retrograde, 122
  - prior to cystography, 119
  - technique, 124
- Uric acid, 32
- Urinalysis, 3–19
  - adrenal-specific urinary tests, 40–42, 68
  - creatinine clearance, 27–28
  - glomerular filtration rate (GFR), 25–27, 28
  - physical examination of
    - urine, 3, 5, 7
    - urine color, 5, 7
  - post-ejaculate, for sperm analysis, 263
  - specimen collection and transport, 3–5
    - in children, 5, 6
    - for cytological analysis, 22–23
  - fractionated urine samples, 4
  - midstream specimen of urine, 3
  - suprapubic aspiration of urine, 3
  - urine from ileal conduits, 5
  - urine from indwelling catheters, 4–5, 22
  - urine from intermittent catheterization, 4
- 24-hour tests
  - for catecholamine metabolites assessment, 68
  - reference ranges for, 32–33, 35
  - for renal calculi detection, 30–34
  - for urinary protein excretion measurement, 28–30
  - urine specific gravity in, 32
  - for urinary acidification assessment, 38–40
  - for urinary electrolyte measurement, 34–38
- urinary markers
  - for prostate cancer detection, 44–46
  - for transitional cell carcinoma detection, 42–44

- Urinalysis (*cont.*)  
urine dipstick analysis, 3, 7–12  
bilirubin content, 12  
blood content, 8, 9  
glucose content, 8, 10  
ketone content, 8, 10–11  
nitrites content, 11  
odor, 7, 8  
pH, 8–9  
protein content, 8, 9–10  
specific gravity, 8  
urobilinogen content, 12  
white blood cell (WBC) content, 11
- Urinary adrenal markers, 40–42, 244
- Urinary frequency, in lower urinary tract disorders, 231
- Urinary incontinence, 227–228  
in children, 256–257  
conditions associated with, 231–232  
cystometry of, 174  
overflow, 231  
pad test for, 203–205  
stress, 231  
pad test for, 203–205  
post-prostatectomy, 186  
pressure-flow cystometry of, 179  
urethral pressure profile in, 184, 186  
videourodynamic evaluation of, 186, 188, 189  
urge, 231  
in children, 257  
vesicoureteral reflex cause-related, 251
- Urinary retention  
chronic, 232  
sphincter electromyography of, 192
- Urinary stones. *See* Calculi, renal
- Urinary tract infections (UTIs)  
bacterial count in, 16, 17, 18, 19  
in children, 253–254  
as cystography  
contraindication, 119  
as cystoscopy  
contraindication, 219  
cystoscopy-related, 217, 219  
diagnosis of, with urine cultures, 17–19  
as loin pain cause, 234  
of lower urinary tract, 228–229  
<sup>99m</sup>Tc-DMSA renographic evaluation of, 1471–48  
recurrent, stress urinary incontinence-related, 227  
as retrograde ureteropyelography  
contraindication, 115  
upper, as loin pain cause, 238–239  
as urethrography  
contraindication, 124  
vesicoureteral reflex cause-related, 251
- Urinary tract obstruction, as loin pain cause, 234, 237–238
- Urinary urgency. *See also* Urinary incontinence, urge  
in lower urinary tract disorders, 231
- Urine  
concentrated, 7  
leakage of

- ambulatory urodynamic evaluation of, 191
- in children, 257
- detrusor overactivity-related, 227
- stress urinary incontinence-related, 227
- urge urinary incontinence-related, 228
- videourodynamic evaluation of, 187
- pH of, 8–9
  - effect on urinary crystal formation, 15–16
  - in 24-hour urine specimens, 32
  - renal calculi-related, 200
  - in renal tubular acidosis, 38, 39–40
- specific gravity of, 8
  - in 24-hour urine specimens, 32
- Urine cultures, 17–19
  - dip-slide method, 17
  - standard surface plating, 17
- Urine flow rate, 139, 166–171
  - effect on glomerular filtration rate, 139
- Urine microscopy. *See* Microscopy, of urine
- Urine tests, 3–46
  - adrenal-specific urinary tests, 40–42
  - creatinine clearance, 27–28
  - cytology, 21–24
  - flow cytometry (DNA ploidy), 19–21
  - glomerular filtration rate, 25–27
  - renal tubular acidosis, 38–40
  - 24-hour urine analysis for recurrent renal calculi, 30–34
  - 24-hour urine for urinary protein excretion, 28–30
- urinalysis, 3–19
  - dipstick analysis, 3
  - microscopic analysis of urine, 3, 12–19
  - physical examination of urine, 3, 5–12
  - specimen collection and transport in, 3–5
- urinary electrolytes, 34–38
- urinary markers for prostate cancer, 44–46
- urinary markers for transitional cell carcinoma, 42, 44
- urine cultures, 17–19
- urine microscopy, 3, 12–17
- Urinoma, 84
- Urobilinogen, urine content of, 12
- Urodynamics, 163–194
  - ambulatory, 189–192
  - of bladder outlet obstruction, 227
  - of chronic pelvic pain/interstitial cystitis, 230
  - conventional, disadvantages of, 189
  - flow rate studies, 166–171
  - frequency volume charts, 163–165
  - pressure-flow cystometry studies, 173–181
  - residual bladder urine volume estimation, 172–173

- Urodynamics (*cont.*)  
  sphincter electromyography, 192–194  
  urethral pressure profile, 168, 181–186  
  videourodynamics, 186–189
- Uroflowmeters, 167–168, 190
- Uroflowmetry, 166–171
- Urological cancers, 240–249
- Uropathy, obstructive,  
  resistive index (RI)  
  in, 118
- Urothelial cells  
  cytology of, 21–24  
  flow cytometry of, 19–21
- Urothelial cell tumors, 244–245
- Ureteropelvic junction  
  obstruction, in  
  children, 250–251, 252
- V**
- Vaginitis, atrophic, 232
- Valine, 35
- Vanillylmandelic acid, 42, 43
- Varicocele, 225, 265  
  ultrasound scanning of, 85
- Vasculature  
  penile, imaging of, 127–129  
  renal, imaging of  
    with computed tomography, 87  
    with Doppler studies, 118  
    with magnetic resonance angiography, 101  
    with magnetic resonance imaging, 104  
    with ultrasound scanning, 84
- Vas deferens, congenital  
  absence of, 215
- Vasectomy, 213, 215
- Vasography, 264
- Vegetarians, alkaline urine  
  in, 9
- Venography, of varicoceles, 225
- Vesicoureteric junction  
  obstruction, pediatric  
  urinary tract  
  infections-related, 253
- Vesicoureteric reflux (VUR)  
  in children, 251–252, 253  
  classification of, 251–252  
  imaging of, 119  
  MAG3 renographic  
    detection of, 145  
  pediatric urinary tract  
  infections-related, 253  
  severe, 231, 232  
  videourodynamic evaluation  
  of, 186, 188
- Vesicoureteric renal stones,  
  imaging of, 85
- Videourodynamics (VUDS),  
  186–189  
  of pediatric urinary  
  incontinence, 257
- Virtual endoscopy, 92–93
- Vitamin D, 61  
  excessive, 62
- Voided urine cytology,  
  22–24  
  for urothelial transitional  
  cell carcinoma  
  detection, 42, 44
- Voiding  
  psychogenic patterns of,  
  165  
  straining during, 168
- Voiding diaries. *See*  
  Frequency volume  
  charts



**W**

Wet chemical analysis, of  
renal calculi, 201,  
202

Whitaker's test, 110, 113,  
252

White blood cells, urine  
content of, 11, 13

**X**

X-ray diffraction, of renal  
calculi, 202

X-rays. *See* Radiographs, plain

**Y**

Yeast, urine content of, 16

Yolk sac tumors, 248